Literature DB >> 25247908

Dexmedetomidine as an adjunctive analgesic with bupivacaine in paravertebral analgesia for breast cancer surgery.

Sahar A Mohamed1, Khaled M Fares, Ashraf Amin Mohamed, Nelly H Alieldin.   

Abstract

BACKGROUND: There is little systematic research on the efficacy and tolerability of the addition of adjunctive analgesic agents in paravertebral analgesia. The addition of adjunctive analgesics, such as fentanyl and clonidine, to local anesthetics has been shown to enhance the quality and duration of sensory neural blockades, and decrease the dose of local anesthetic and supplemental analgesia.
OBJECTIVES: Investigation of the safety and the analgesic efficacy of adding 1 μg/kg dexmedetomidine to bupivacaine 0.25% in thoracic paravertebral blocks (PVB) in patients undergoing modified radical mastectomy. STUDY
DESIGN: A randomized, double-blind trial.
SETTING: Academic medical center.
METHODS: Sixty American Society of Anesthesiologists physical status -I - III patients were randomly assigned to receive thoracicPVB with either 20 mL of bupivacaine 0.25% (Group B, n = 30), or 20 mL of bupivacaine 0.25% + 1 μg/kg dexmedetomidine (Group BD, n= 30). Assessment parameters included hemodynamics, sedation score, pain severity, time of first analgesics request, total analgesic consumption, and side effects in the first 48 hours.
RESULTS: There was a significant reduction in pulse rate and diastolic blood pressure starting at 30 minutes in both groups, but more evidenced in group BD (P < 0.001). Intraoperative Systolic blood pressure showed a significant reduction at 30 minutes in both groups (P < 0.001) then returned to baseline level at 120 minutes in both groups. There was a significant increase in pulse rate starting 2 hours postoperative until 48 hours postoperatively in group B but only after 12 hours until 48 hours in group BD (P < 0.001). The time of the first rescue analgesic requirement was significantly prolonged in the group BD (8.16 ± 42 hours) in comparison to group B (6.48 ± 5.24 hours) (P = 0.04). The mean total consumption of intravenous tramadol rescue analgesia in the postanesthesia care unit in the firtst 48 hours postoperatively was significantly decreased in group BD (150.19 ± 76.98 mg) compared to group B (194.44 ± 63.91 mg) (P = 0.03). No significant serious adverse effects were recorded during the study. LIMITATIONS: This study is limited by its sample size.
CONCLUSION: The addition of dexmedetomidine 1 μg/kg to bupivacaine 0.25% in thoracic PVB in patients undergoing modified radical mastectomy improves the quality and the duration of analgesia and also provides an analgesic sparing effect with no serious side effects.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25247908

Source DB:  PubMed          Journal:  Pain Physician        ISSN: 1533-3159            Impact factor:   4.965


  27 in total

1.  Protective role of LRRC3B in preventing breast cancer metastasis and recurrence post-bupivacaine.

Authors:  Gong-Sheng Li; Gao-Yin Kong; Yi Zou
Journal:  Oncol Lett       Date:  2017-08-18       Impact factor: 2.967

2.  Efficacy of dexmedetomidine as an adjuvant in paravertebral block in breast cancer surgery.

Authors:  Medha Mohta; Bhumika Kalra; Ashok K Sethi; Navneet Kaur
Journal:  J Anesth       Date:  2015-12-22       Impact factor: 2.078

3.  Effects of fentanyl and dexmedetomidine as adjuvants to bupivacaine in paravertebral block for postoperative analgesia in patients undergoing modified radical mastectomy: A prospective randomised double-blind study.

Authors:  Nibedita Pani; Padmalaya Sahu; Deepti Swain; Chetna Biswal; Amit Pradhan; Sidharth Sraban Routray
Journal:  Indian J Anaesth       Date:  2022-06-06

4.  Comparative Study of Epidural Dexmedetomidine, Fentanyl, and Tramadol as Adjuvant to Levobupivacaine for Lower Limb Orthopedic Surgeries.

Authors:  Usha Shukla; Dheer Singh; Jheelam Singh; Jay Brijesh Singh Yadav
Journal:  Cureus       Date:  2022-05-22

5.  Comparison of dexmedetomidine and dexamethasone as adjuvant for ropivacaine in ultrasound-guided erector spinae plane block for video-assisted thoracoscopic lobectomy surgery: a randomized, double-blind, placebo-controlled trial.

Authors:  Zhixin Gao; Yimin Xiao; Qing Wang; Yuanhai Li
Journal:  Ann Transl Med       Date:  2019-11

6.  Dexmedetomidine Improves Postoperative Patient-Controlled Analgesia following Radical Mastectomy.

Authors:  Wei Fan; Hong Xue; Yong Sun; HaiKou Yang; Jun Zhang; Guangming Li; Ying Zheng; Yi Liu
Journal:  Front Pharmacol       Date:  2017-05-09       Impact factor: 5.810

7.  Intraoperative use of dexmedetomidine promotes postoperative sleep and recovery following radical mastectomy under general anesthesia.

Authors:  Cunxian Shi; Jin Jin; Qiang Pan; Shan Song; Kezhong Li; Jiahai Ma; Tao Li; Zhi Li
Journal:  Oncotarget       Date:  2017-05-24

Review 8.  Dexmedetomidine in perioperative acute pain management: a non-opioid adjuvant analgesic.

Authors:  Chaoliang Tang; Zhongyuan Xia
Journal:  J Pain Res       Date:  2017-08-11       Impact factor: 3.133

9.  Single Shot Adductor Canal Block for Postoperative Analgesia of Pediatric Patellar Dislocation Surgery: A Case-Series Report.

Authors:  Jia-Yu Chen; Na Li; Yong-Qing Xu
Journal:  Medicine (Baltimore)       Date:  2015-12       Impact factor: 1.817

10.  Evaluation of the role of dexmedetomidine in improvement of the analgesic profile of thoracic paravertebral block in thoracic surgeries: A randomised prospective clinical trial.

Authors:  Mohamed Elsayed Hassan; Essam Mahran
Journal:  Indian J Anaesth       Date:  2017-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.